Sensitivity of three serum antibody tests in a large outbreak of Legionnaires' disease in the Netherlands

Ed P. F. Yzerman,^{1,2} Jeroen W. den Boer,³ Kamilla D. Lettinga,² Arnoud J. Schel,² Joop Schellekens⁴ and Marcel Peeters⁵

Correspondence

Ed P. F. Yzerman

e.yzerman@streeklabhaarlem.nl

¹Regional Laboratory of Public Health Haarlem, Boerhaavelaan 26, 2035 RC Haarlem, The Netherlands

²Academic Medical Center, Amsterdam, The Netherlands

³Municipal Health Service Kennemerland, Haarlem, The Netherlands

⁴National Institute for Public Health and the Environment, Bilthoven, The Netherlands

⁵Regional Laboratory of Public Health Tilburg, Tilburg, The Netherlands

In 1999, an outbreak involving 188 patients with Legionnaires' disease (LD) occurred at a flower show in the Netherlands. This large outbreak provided the opportunity to evaluate serum antibody tests to assay anti-*Legionella pneumophila*, since limited data are available on the sensitivity of these tests. The sensitivities of an indirect serotype 1-6 immunofluorescence antibody test (IFAT), a rapid micro-agglutination test (RMAT) IgM serotype 1 antibody assay, and an ELISA to detect IgM and IgG serotype 1-7 antibodies, were evaluated using serum samples from LD patients related to the 1999 outbreak. Sensitivity was calculated using positive culture and/or a positive urinary antigen test as the gold standard in outbreak-related patients with radiographically confirmed pneumonia who fulfilled the epidemiological criteria. The IFAT, RMAT and ELISA showed sensitivities of 61, 44 and 64 %, respectively. The sensitivity of the three tests combined was 67 %. In epidemic situations, however, high standing titres may be included in the laboratory evidence of LD cases. In the study population, high standing titres were found in 16 % of cases. If the presence of high standing antibody titres was added to the criteria of a positive test, the sensitivities of IFAT, RMAT and ELISA were 86, 48 and 75 %, respectively. The sensitivity was 91 % for all tests combined. The higher sensitivity for the combined use of tests is offset by a reduction in specificity to 97.6 %. The results of this study indicate that using a combination of serologic tests in pneumonia patients suspected to have LD does not substantially improve sensitivity. The results suggest that in the microbiological diagnosis of LD, both IFAT and ELISA are reasonably sensitive assays. In an epidemic situation, both tests are highly sensitive, the IFAT more so than the ELISA.

Received 11 October 2005

Accepted 26 January 2006

INTRODUCTION

Legionnaires' disease (LD) is an acute pneumonia caused by *Legionella* spp., which are responsible for 2–5 % of community-acquired pneumonias (CAPs) (Marston *et al.*, 1997; Bohte *et al.*, 1995). Patients are infected by inhalation of aerosols containing *Legionella* spp. or by aspiration of water contaminated with *Legionella* spp. Over 90 % of LD cases are caused by *Legionella pneumophila*, of which 70–80 % belong to serogroup type 1 (Yu *et al.*, 2002;

Marston *et al.*, 1997). Although over 90 % of LD cases are sporadic, much can be learned from outbreak-related LD cases, including their microbiological diagnosis. Diagnosis of LD is mainly based on culture, antigen detection in urine, and antibody detection in serum. Culturing of *Legionella* spp. from respiratory secretions has a sensitivity ranging from 25 to 75 % (Hoge & Breiman, 1991). Urinary antigen tests, both enzyme immunoassay (EIA) and immunochromatographic assay (ICT) combine a 99 % or higher specificity with a sensitivity ranging from 50 to 90 % (Birtles *et al.*, 1990; Dominguez *et al.*, 1998, 1999; Ruf *et al.*, 1990). Serological tests to identify antibodies to *L. pneumophila* were developed from 1977 onwards, starting with the indirect immunofluorescence antibody test (IFAT) (McDade *et al.*, 1977). Several less laborious serological tests

Abbreviations: CAP, community-acquired pneumonia; EWGLI, European Working Group on Legionella Infections; IFAT, immunofluorescence antibody test; LD, Legionnaires' disease; RMAT, rapid micro-agglutination test.

followed, among them numerous (mostly experimental) ELISAs and a micro-agglutination test (MAT). The first publication on an ELISA was in 1978 (Farshy *et al.*, 1978). Although commercial ELISA kits have become widely used, few studies of their sensitivity and specificity have been published. The same holds for the MAT, which was also developed in 1978; this was followed by a rapid version, the rapid micro-agglutination test (RMAT), with identical test characteristics, in 1982 (Harrison & Taylor, 1982). The sensitivity of all three assays has been tested using sporadic cases of LD and not in outbreak situations. A recent outbreak in the Netherlands (den Boer *et al.*, 2002) provided a unique opportunity to evaluate the sensitivity of three serum antibody tests. This outbreak was caused by a *L. pneumophila* serogroup 1 strain. The nationwide alert for LD cases ensured optimal case finding, thereby decreasing patient selection bias. Furthermore, the outbreak situation allowed us to take the clinical spectrum into account, since all available clinical data for the LD patients related to this outbreak were recorded centrally. In addition, the conditions for a gold standard were favourable: two national reference laboratories performed all microbiological tests and a large collection of samples from a national serum bank was available to investigate the distribution of antibodies to *L. pneumophila* serogroup 1 among the Dutch population. To assess the sensitivity of the detection of serum *Legionella* antibodies, we performed three tests on serum specimens from outbreak-related LD cases: a serotype 1-6 antibody IFAT, an IgM serotype 1 antibody RMAT, and an ELISA to detect IgM and IgG serotype 1-7 antibodies (Boshuizen *et al.*, 2003). The aim of our study was to compare the sensitivities of the three tests using confirmative and epidemic LD criteria, to see if combined use of the three tests would be justified, and to compare our results to published sensitivities of IFAT, RMAT and ELISA in both epidemic and non-epidemic settings.

METHODS

The outbreak. In February 1999, an outbreak involving 133 confirmed and 55 probable cases of LD, according to the European Working Group on Legionella Infections (EWGLI) criteria (Anonymous, 1998), occurred in Bovenkarspel in the Netherlands. Of these patients, 89% were hospitalized. The outbreak investigation indicated that a whirlpool displayed at the consumer product division of an annual flower show was the most likely source of infection. Two *L. pneumophila* serogroup 1 strains were cultured from sputum of 29 patients. One of the strains was of the Allentown/France serogroup 1 subtype (Helbig *et al.*, 2002) and was genotyped 010-London according to the EWGLI criteria (Fry *et al.*, 2000). This strain was identified in 28 of the 29 culture-positive patients. Genotyping of the environmental *L. pneumophila* strains revealed that one *L. pneumophila* serogroup 1 strain found in the implicated whirlpool was of the 010-London genotype as well (Den Boer *et al.*, 2002).

Patients. In this study, 133 patients with a confirmed *Legionella* pneumonia according to the EWGLI criteria were included after having obtained written consent from them or from their relatives. Of these patients, 104 fulfilled the criteria of the gold standard used in this study. The gold standard (identical to the EWGLI criteria, but excluding serological evidence of infection) was defined as a

patient who had symptoms compatible with pneumonia, with radiological signs of infiltration, who had visited the site of the outbreak during the incubation period, and who had laboratory evidence of infection with *L. pneumophila*. Laboratory evidence included at least one of the following criteria:

- (1) Isolation of *L. pneumophila* from a respiratory sample cultured on buffered charcoal yeast extract supplemented with 2-ketoglutarate (BCYA- α), followed by genotyping and subsequent comparison to the environmental strain of the Bovenkarspel outbreak.
- (2) Presence of *L. pneumophila* antigens in urine specimens, as shown in an antigen test. The three tests used in our study were two enzyme immunoassays, the Binax (Binax, Portland, ME, USA) and Biotest (Biotest AG, Dreieich, Germany) *Legionella* urinary antigen tests, and the BinaxNOW test, a qualitative immunochromatographic assay. All tests were used according to the manufacturers' instructions. Urine was concentrated and reread after 1 h, as recommended (Dominguez *et al.*, 1996; Helbig *et al.*, 2001).
- (3) All isolates from sputum samples were sent to the National Institute for Public Health and the Environment (RIVM) for genotyping of *L. pneumophila*. The Regional Laboratories of Public Health of Tilburg and Haarlem were the reference laboratories for the detection of *L. pneumophila* antigen in urine.

Classification of severity of disease. To evaluate exclusion bias by differences in severity of disease, the patients were divided into three clinical categories for CAP. Clinical data were collected from the hospital chart using a standardized case record form. Severity of pneumonia was scored on a five-point scale (0–4), according to the minor criteria for severity of CAP (Niederman *et al.*, 1993), using the following clinical criteria at hospital admission: (1) respiratory frequency above 30 breaths per minute, (2) PaO₂ below 60 mm Hg or O₂ saturation below 92%, (3) bilateral or multilobar infiltration on chest X-ray, 4) systolic blood pressure below 90 mm Hg or diastolic below 60 mm Hg.

Patients with a radiographically proven unilateral unilobar pneumonia, but without signs or symptoms according to the above-mentioned criteria, were classified as CAP category 1 (mild pneumonia). CAP category 2 consisted of patients who fulfilled only one of the criteria. According to our definition, these patients were suffering from a moderately severe pneumonia. CAP category 3 consisted of patients who presented themselves with two or more criteria and were considered to suffer from a severe pneumonia.

Serum samples and serum antibody tests. All 62 laboratories of clinical microbiology involved in diagnosis and treatment of the patients related to this outbreak sent all available serum samples to the Regional Laboratory of Public Health in Haarlem. After collection, serum samples were stored in portions at -70°C .

The criteria for a paired serum sample confirmative for LD were defined as:

- (1) A fourfold rise in IgG, IgM and/or IgA antibodies to *L. pneumophila* in paired acute-phase (0–15 days after disease onset) and convalescent-phase sera, with final titre $\geq 1:128$, using a commercial serotype 1-6 antibody IFAT (Polyvalent *Legionella* IFA Test Kit Serogroups 1-6, Meridian Bioscience Europe Srl.) (McDade *et al.*, 1977).
- (2) A fourfold rise in IgM antibodies to *L. pneumophila* in paired acute-phase (0–15 days after disease onset) and convalescent-phase sera, with final titre $\geq 1:32$ in accordance with the 99% cut-off value found in a serosurvey among healthy volunteers representative of the Dutch population (Boshuizen *et al.*, 2003), using an IgM, serogroup 1 Philadelphia-I subtype, antibody RMAT (Farshy *et al.*, 1978).

(3) Seroconversion to positive IgM or IgG antibodies to *L. pneumophila* in paired acute-phase (0–15 days after disease onset) and convalescent-phase sera, in accordance with the age-specific 99 % cut-off values found in a serosurvey among healthy volunteers representative of the Dutch population (Boshuizen *et al.*, 2003), using a commercial ELISA to detect IgM and IgG serotype 1–7 antibodies (Serion classic ELISA, Institut Virion/Serion GmbH, Würzburg, Germany) (Etienne *et al.*, 1999). The antigens in this test are prepared from cultures of different *L. pneumophila* serogroups and subtypes: serogroup 1 Knoxville and Philadelphia subtypes, serogroup 2 Togus-1 subtype, serogroup 3 Bloomington-2 subtype, serogroup 4 Los Angeles-1 subtype, serogroup 5 Dallas-1 subtype, serogroup 6 Chicago-2 subtype, and serogroup 7 Chicago-8 subtype.

The criteria for a paired serum sample suggestive for LD used in an epidemic situation were defined as:

(1) High standing titres of IgG, IgM and/or IgA antibodies to *L. pneumophila* in paired acute-phase (0–15 days after disease onset) and convalescent-phase sera, with final titre $\geq 1:128$ using a serotype 1–6 antibody IFAT, as described above.

(2) High standing titres of IgM antibodies to *L. pneumophila* in paired acute-phase (0–15 days after disease onset) and convalescent-phase sera, with final titre $\geq 1:32$ using an IgM antibody RMAT, as described above.

(3) High standing titres of IgM or IgG antibodies to *L. pneumophila* in paired acute-phase (0–15 days after disease onset) and convalescent-phase sera using an ELISA to detect IgM and IgG serotype 1–7 antibodies, as described above.

Sensitivity. Sensitivity was defined as the number of patients with a positive test result divided by the total number of patients tested. Sensitivity for confirmed LD was calculated using the confirmative criteria for LD. Sensitivity for an epidemic situation was calculated using the confirmative and the suggestive criteria for LD.

Statistics. Statistical analysis was performed with the statistical program SPSS version 12.0 (Statistical Product and Service Solutions). Univariate analysis was used to identify factors potentially associated with test positivity: age, gender, clinical severity, number of days passed between onset of disease and collection of the first serum sample, and number of serum samples taken.

Fig. 1. Selection of LD patients in this study. UAG, urinary antigen.

RESULTS AND DISCUSSION

Two or more properly timed serum samples with complete sampling dates were available for evaluation from 45 of the 104 hospitalized patients who fulfilled the criteria of the gold standard used in this study (see Fig. 1 for patient selection). Table 1 shows that excluded patients died significantly more often from LD, although their CAP score

Table 1. Differences between 45 included and 59 excluded LD patients for factors possibly associated with exclusion bias

CAP category 1=mild pneumonia; CAP category 2=moderately severe pneumonia; CAP category 3=severe pneumonia.

Factor	Proportion of included patients	Proportion of excluded patients
Proportion of male gender	60 %	68 %
Mean age in years (range)	63 (21–78)	65 (25–84)
CAP category 1	27 %	26 %
CAP category 2	32 %	31 %
CAP category 3	41 %	43 %
Admission to intensive care unit	43 %	34 %
Fatal outcome	9 %	24 %*

*Difference is statistically significant.

Table 2. Timing of convalescent serum sample(s) and presence of antibodies to *L. pneumophila*, as demonstrated by any of three assays, for 45 LD patients for whom two or more properly timed sera were available

Time	No. of patients with available sera	Standing titre*	Fourfold rise in titre or seroconversion
2–6 weeks	37	6/37	22/37
6–12 weeks	12	0/12	4/12
More than 12 weeks	20	1/20	4/20

*Acute-phase serum was positive.

distribution was very similar to that of the included patients. Of the 45 included patients, 26 were men, with a mean age of 64 years (range 46–78 years) and 19 were women with a mean age of 60 years (range 21–77 years). The microbiological diagnosis was established by culture alone in one case, by culture and by urinary antigen test in nine cases and by urinary antigen test alone in 35 cases. The first serum to be tested for antibodies against *L. pneumophila* was collected 0–15 days (mean 8 days) after the first day of signs and symptoms of pneumonia. From 22 patients two sera were available, from 13 patients three sera were available and from 10 patients four to eight sera were available for evaluation. Table 2 shows the timing of the convalescent sera. For one of the patients, the volume of serum was too small to perform all three tests, so only the RMAT test was performed. Patients with positive test results on average had their first serum taken 2 days earlier in the acute phase than patients with high standing titres: 7.1 versus 9.4 days after disease onset. This finding may suggest that in LD cases with high standing antibody titres, seroconversion had already occurred. In total, 7/45 (16%) of patients showed high standing titres in all assays. Table 3 shows the sensitivities of the three tests and the sensitivity for the combination of all tests for both the non-epidemic and epidemic criteria. Evaluating the ELISA for its individual components, sera from 48% of the patients showed a seroconversion in IgM ELISA and 50% a seroconversion in IgG ELISA. Using

the epidemic criteria, the sensitivities were 61 and 64%, respectively.

It seems that the superior sensitivity of the IFAT and ELISA compared to the RMAT was mostly due to the identification of antibodies other than IgM. In this outbreak, the combination of tests was of limited value.

It has been suggested that in LD, any diagnostic test with a specificity below 99% is unacceptable (Hoge & Breiman, 1991). Most IFAT sensitivity studies use this criterion and show similar results in non-outbreak patient series. However, the sensitivity for the IFAT in the Philadelphia outbreak was 42% for a fourfold rise in titre, given a specificity of 99.1%. With high standing titres added to the criteria of an LD case, sensitivity was 68% (McDade *et al.*, 1977). The IFAT used in our study seems more sensitive, probably due to the use of a polyvalent conjugate directed against IgG, IgM and IgA antibodies.

The sensitivity of the RMAT was 63% in a study evaluating sera from 119 patients with LD using a positive culture for *L. pneumophila* or its presence shown by direct fluorescence antibody as the gold standard (Harrison *et al.*, 1987). The substantially higher sensitivity of the RMAT assay found in that study (63 versus 44% in our study) is difficult to explain. A different strain of *L. pneumophila* serogroup 1 was used, but the influence of different strains on RMAT

Table 3. Sensitivity of three serum *L. pneumophila* antibody tests using sera from 45 LD patients

Test criterion	Sensitivity
Fourfold rise in IFAT	61% (27/44)
Fourfold rise in RMAT	44% (20/45)
Seroconversion in IgM or IgG ELISA	64% (28/44)
Combination of the three tests above	67% (30/45)
Fourfold rise or high standing titres in IFAT	86% (38/44)
Fourfold rise or high standing titres in RMAT	58% (26/45)
Seroconversion or high standing titres in IgM or IgG ELISA	75% (33/44)
Combination of the three tests above	91% (41/45)

sensitivity is unknown. There was a difference in the timing of the first serum sample (0–28 days after disease onset in the study of Harrison *et al.*, 1987), but late sampling tends to underestimate the sensitivity. There were differences in study population: higher clinical severity, higher mortality, and over 50 % immunocompromised patients in the study of Harrison *et al.* (1987).

To our knowledge, only two reports are available describing data from which an ELISA sensitivity based on a 99 % or higher specificity could be inferred (Bangsborg *et al.*, 1994; Wreghitt *et al.*, 1982). Bangsborg *et al.* (1994) studied convalescent sera from 20 culture-proven LD patients and described an ELISA based on a lipopolysaccharide antigen with sensitivities of 70 % for IgM and 75 % for IgG, respectively. Although in the Bangsborg *et al.* (1994) study the sensitivity of an IgM and IgG ELISA combination is not described, the reported individual sensitivities are 10 % higher than those found in our study. This may be due to a difference in the antigen used or a difference in study population. Wreghitt *et al.* (1982) studied sera from 11 patients and found sensitivities of 58 and 41 % for IgM and IgG ELISA, respectively. In the Wreghitt *et al.* (1982) study, another serum antibody test was included in the gold standard, and no details were given concerning the timing of serum samples under study, complicating comparison to our data.

In conclusion, to diagnose *L. pneumophila* pneumonia, serology is still a valuable tool. This study is the first to compare the sensitivities of an IFAT, an RMAT and an ELISA in an outbreak situation. The IFAT and ELISA seem to yield similar results using confirmative LD criteria. In an epidemic situation, the IFAT seems superior. Combination of assays in an outbreak situation improves sensitivity only marginally, from 86 to 91 %. The data from this study suggest that early sampling may lead to a higher sensitivity for all tests.

ACKNOWLEDGEMENTS

We thank all hospital clinicians and microbiologists for requesting patients' permission and allowing us to collect clinical data and serum samples. Special thanks to Yvonne Boelens and Jacob P. Bruin, who performed the serum antibody tests.

REFERENCES

- Anonymous (1998).** Legionnaires' disease in Europe. *Wkly Epidemiol Rec* 73, 257–261.
- Bangsborg, J. M., Shand, G. H., Hansen, K. & Wright, J. B. (1994).** Performance of four different indirect enzyme-linked immunosorbent assays (ELISAs) to detect specific IgG, IgA, and IgM in Legionnaires' disease. *APMIS* 102, 501–508.
- Birtles, R. J., Harrison, T. G., Samuel, D. & Taylor, A. G. (1990).** Evaluation of urinary antigen ELISA for diagnosing *Legionella pneumophila* serogroup 1 infection. *J Clin Pathol* 43, 685–690.
- Bohte, R., van Furth, R. & van den Broek, P. J. (1995).** Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital. *Thorax* 50, 543–547.
- Boshuizen, H. C., Den Boer, J. W., De Melker, H., Schellekens, J. F., Peeters, M. F., van Vliet, J. A. & Conyn-van Spaendonck, M. A. (2003).** Reference values for the SERION classic ELISA for detecting *Legionella pneumophila* antibodies. *Eur J Clin Microbiol Infect Dis* 22, 706–708.
- Den Boer, J. W., Yzerman, E. P., Schellekens, J. & 11 other authors. (2002).** A large outbreak of Legionnaires' disease at a flower show, the Netherlands, 1999. *Emerg Infect Dis* 8, 37–43.
- Dominguez, J. A., Manterola, J. M., Blavia, R. & 7 other authors. (1996).** Detection of *Legionella pneumophila* serogroup 1 antigen in nonconcentrated urine and urine concentrated by selective ultrafiltration. *J Clin Microbiol* 34, 2334–2336.
- Dominguez, J. A., Gali, N., Pedrosa, P., Fargas, A., Padilla, E., Manterola, J. M. & Matas, L. (1998).** Comparison of the Binax *Legionella* urinary antigen enzyme immunoassay, (EIA) with the Biotest *Legionella* Urin antigen EIA for detection of *Legionella* antigen in both concentrated and nonconcentrated urine samples. *J Clin Microbiol* 36, 2718–2722.
- Dominguez, J., Gali, N., Matas, L., Pedrosa, P., Hernandez, A., Padilla, E. & Ausina, V. (1999).** Evaluation of a rapid immunochromatographic assay for the detection of *Legionella* antigen in urine samples. *Eur J Clin Microbiol Infect Dis* 18, 896–898.
- Etienne, J., Vandenesch, F. & Lina, G. Jarraud (1999).** Evaluation des SERION ELISA classic *Legionella pneumophila* 1–7 (IgG, IgM). Leusden, The Netherlands: Clindia Benelux bv.
- Farshy, C. E., Klein, G. C. & Feeley, J. C. (1978).** Detection of antibodies to Legionnaires disease organism by microagglutination and micro-enzyme-linked immunosorbent assay tests. *J Clin Microbiol* 7, 327–331.
- Fry, N. K., Bangsborg, J. M., Bernander, S. & 11 other authors. (2000).** Assessment of intercentre reproducibility and epidemiological concordance of *Legionella pneumophila* serogroup 1 genotyping by amplified fragment length polymorphism analysis. *Eur J Clin Microbiol Infect Dis* 19, 773–780.
- Harrison, T. G. & Taylor, A. G. (1982).** A rapid microagglutination test for the diagnosis of *Legionella pneumophila* (serogroup 1) infection. *J Clin Pathol* 35, 1028–1031.
- Harrison, T. G., Dournon, E. & Taylor, A. G. (1987).** Evaluation of sensitivity of two serological tests for diagnosing pneumonia caused by *Legionella pneumophila* serogroup 1. *J Clin Pathol* 40, 77–82.
- Helbig, J. H., Uldum, S. A., Luck, P. C. & Harrison, T. G. (2001).** Detection of *Legionella pneumophila* antigen in urine samples by the BinaxNOW immunochromatographic assay and comparison with both Binax *Legionella* Urinary Enzyme Immunoassay, (EIA) and Biotest *Legionella* Urin Antigen, EIA. *J Med Microbiol* 50, 509–516.
- Helbig, J. H., Bernander, S., Castellani, P. M. & 13 other authors. (2002).** Pan-European study on culture-proven Legionnaires' disease: distribution of *Legionella pneumophila* serogroups and monoclonal subgroups. *Eur J Clin Microbiol Infect Dis* 21, 710–716.
- Hoge, C. W. & Breiman, R. F. (1991).** Advances in the epidemiology and control of *Legionella* infections. *Epidemiol Rev* 13, 329–340.
- Marston, B. J., Plouffe, J. F., File, T. M., Jr, Hackman, B. A., Salstrom, S. J., Lipman, H. B., Kolczak, M. S. & Breiman, R. F. (1997).** Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio. The Community-Based Pneumonia Incidence Study Group. *Arch Intern Med* 157, 1709–1718.
- McDade, J. E., Shepard, C. C., Fraser, D. W., Tsai, T. R., Redus, M. A. & Dowdle, W. R. (1977).** Legionnaires' disease: isolation of a

bacterium and demonstration of its role in other respiratory disease. *N Engl J Med* **297**, 1197–1203.

Niederman, M. S., Bass, J. B., Jr, Campbell, G. D. & 7 other authors. (1993). Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy, American Thoracic Society. Medical Section of the American Lung Association. *Am Rev Respir Dis* **148**, 1418–1426.

Ruf, B., Schurmann, D., Horbach, I., Fehrenbach, F. J. & Pohle, H. D. (1990). Prevalence and diagnosis of *Legionella pneumoniae*: a 3-year

prospective study with emphasis on application of urinary antigen detection. *J Infect Dis* **162**, 1341–1348.

Wreghitt, T. G., Nagington, J. & Gray, J. (1982). An ELISA test for the detection of antibodies to *Legionella pneumophila*. *J Clin Pathol* **35**, 657–660.

Yu, V. L., Plouffe, J. F., Pastoris, M. C. & 8 other authors. (2002). Distribution of *Legionella* species and serogroups isolated by culture in patients with sporadic community-acquired legionellosis: an international collaborative survey. *J Infect Dis* **186**, 127–128.